When are "positive" clinical trials in oncology truly positive?
about
A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In VivoMedicines for cancers in children: The WHO model for selection of essential medicines.Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.Fool's gold, lost treasures, and the randomized clinical trial.Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?Tough decisions on essential medicines in 2015.Increasing value and reducing waste in research design, conduct, and analysisPopulation-based trends in systemic therapy use and cost for cancer patients in the last year of life.Somatic variation and cancer: therapies lost in the mix.Natural polyphenols in cancer therapy.Evidence appraisal: a scoping review, conceptual framework, and research agenda.Evaluation of Research Ethics Committees: Criteria for the Ethical Quality of the Review Process.Predicting responses to chemotherapy in the context that matters - the patient.Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation.Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagementAvailability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.A peculiar prevalence of p values just below .05.Prognostic Value of Conventional Magnetic Resonance Imaging for Adult Patients with Brain Tumors.Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer.Should be NICE have a Spanish NICE?Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.Avoidable waste of research related to outcome planning and reporting in clinical trials.The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs
P2860
Q28552262-EFB137A7-CEE3-4CBA-8505-304F51B935D4Q30380209-D6945C47-91CC-4AD7-BC94-544DCD07CBC4Q33834080-13097DC2-468D-44E4-BDBD-A436090B2CA9Q34669260-89C94FF9-D7FE-45E4-9C97-421F1E1D0A5EQ35223735-06A94EEB-5BFD-4FCE-8AB7-DE7C79FA7030Q35606112-5F70F569-658F-4DCB-83B9-210411154515Q36420861-00CD1E2D-3217-4AD1-85AC-70D4719C2926Q36658837-A90117A5-F137-488F-97C7-8436DE626421Q37885276-7C510788-92EC-4349-BEC7-E7D96849883FQ37964733-6BA9BA4C-1F98-413C-B7FC-3FDF7ABB3F40Q38765450-17CB905A-F5FA-4265-A709-7B8C80CF534AQ39049219-34B37BCF-E1CD-4D0F-96BB-30BB7E54226CQ40631259-41DDAD2B-2BC5-4285-B6F4-93520990230FQ41275697-BB41D003-9CFC-45B1-A95C-09163C799E38Q41592587-554CC514-334A-4BE4-B5C6-B61F053CB05CQ42281334-E56455C9-DD71-4B81-B8C7-FD364C565F0DQ43447558-BC16A4CB-427C-4886-B856-997B396A03A2Q44141338-45FD9751-8D17-45A0-9E94-F72C3B0C3369Q44617042-571F8795-81C3-40B8-B49F-2405FE505881Q44898207-B84E20FF-DADB-4C1C-B264-49C06E000323Q47591645-5B82F62C-06E9-4A56-8240-4A0C3C4499CCQ49824585-E5FFC9B1-B0D5-45F5-9C29-B6D8E877FE9EQ51249026-DF7E16BB-5264-428A-9AB8-BB8D55739C52Q52590080-7641CE7B-A59D-4AEA-90DC-F57DAEEC1AD9Q55475456-A7436FED-06AA-46F9-9D72-33D0E7CF00DDQ58718992-B283FD31-6E27-4DBD-B345-6B323E0107B7
P2860
When are "positive" clinical trials in oncology truly positive?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
When are "positive" clinical trials in oncology truly positive?
@en
When are "positive" clinical trials in oncology truly positive?
@nl
type
label
When are "positive" clinical trials in oncology truly positive?
@en
When are "positive" clinical trials in oncology truly positive?
@nl
prefLabel
When are "positive" clinical trials in oncology truly positive?
@en
When are "positive" clinical trials in oncology truly positive?
@nl
P2860
P356
P1476
When are "positive" clinical trials in oncology truly positive?
@en
P2093
Ian F Tannock
P2860
P356
10.1093/JNCI/DJQ463
P407
P577
2010-12-03T00:00:00Z